Biosimilars — nearly identical versions of biologic drugs — have been heralded as a salve for the skyrocketing costs of prescription medications used to treat a wide variety of diseases. But so far they have been a disappointment. In this STAT Report, we dive into the regulations and manufacturing limitations that have acted as barriers to entry, as well as the companies that have managed to succeed in the space. Learn more about this report.

Gene therapies were once dismissed as too dangerous to introduce to the treatment landscape. But today they are making a comeback with hundreds of products in the pipeline and under trial. In our latest STAT Report, we dive into the science, and business, of viral vector technologies. We spoke with executives from 18 companies to identify the pipeline of therapies that are nearing the clinic, the engineering and production challenges that may stifle progress, and how key players are looking to overcome those challenges. Learn more about this report.

This 100-page report profiles each of the Democratic hopefuls running for president in 2020 — including long-shot candidates who may nevertheless be seen as picks for vice president or cabinet roles — and analyzes their positions on drug pricing. This is an ideal report for pharma insiders, policymakers, and staffers alike, regardless of how closely you’ve been following the 2020 race so far. It provides a comprehensive understanding of how the election is likely to influence public policy debates around the country in the coming year, and what a change of party in the White House could mean for the industry overall. Learn more about this report.

This 140-page report takes a look at more than 50 venture capital firms that invest in biotechnology — from firms that specialize in biotech (or in health care in general), to generalists who are pumping money into the broader technology sector, with biotech as part of the mix. Learn more about this report.